Literature DB >> 27256650

A decade of Australian methotrexate dosing errors.

Rose Cairns1, Jared A Brown2, Ann-Maree Lynch3, Jeff Robinson4, Carol Wylie5, Nicholas A Buckley2.   

Abstract

OBJECTIVE: Accidental daily dosing of methotrexate can result in life-threatening toxicity. We investigated methotrexate dosing errors reported to the National Coronial Information System (NCIS), the Therapeutic Goods Administration Database of Adverse Event Notifications (TGA DAEN) and Australian Poisons Information Centres (PICs). DESIGN AND
SETTING: A retrospective review of coronial cases in the NCIS (2000-2014), and of reports to the TGA DAEN (2004-2014) and Australian PICs (2004-2015). Cases were included if dosing errors were accidental, with evidence of daily dosing on at least 3 consecutive days. MAIN OUTCOME MEASURES: Events per year, dose, consecutive days of methotrexate administration, reasons for the error, clinical features.
RESULTS: Twenty-two deaths linked with methotrexate were identified in the NCIS, including seven cases in which erroneous daily dosing was documented. Methotrexate medication error was listed in ten cases in the DAEN, including two deaths. Australian PIC databases contained 92 cases, with a worrying increase seen during 2014-2015. Reasons for the errors included patient misunderstanding and incorrect packaging of dosette packs by pharmacists. The recorded clinical effects of daily dosage were consistent with those previously reported for methotrexate toxicity.
CONCLUSION: Dosing errors with methotrexate can be lethal and continue to occur despite a number of safety initiatives in the past decade. Further strategies to reduce these preventable harms need to be implemented and evaluated. Recent suggestions include further changes in packet size, mandatory weekly dosing labelling on packaging, improving education, and including alerts in prescribing and dispensing software.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27256650     DOI: 10.5694/mja15.01242

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


  7 in total

1.  Opportunities for changes in the drug product design to enhance medication safety in older people: Evaluation of a national public portal for medication incidents.

Authors:  Fatma Karapinar-Çarkit; Patricia M L A van den Bemt; Mariam Sadik; Brigit van Soest; Wilma Knol; Florence van Hunsel; Diana A van Riet-Nales
Journal:  Br J Clin Pharmacol       Date:  2020-06-24       Impact factor: 4.335

2.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

3.  Trends and variation in unsafe prescribing of methotrexate: a cohort study in English NHS primary care.

Authors:  Brian MacKenna; Helen J Curtis; Alex J Walker; Richard Croker; Seb Bacon; Ben Goldacre
Journal:  Br J Gen Pract       Date:  2020-06-25       Impact factor: 5.386

4.  Methotrexate Pneumonitis After a Low-Dose Medication Error: A Case Report.

Authors:  Maria Manuel Silva; Carla Campinho Ferreira; Maria Afonso Garcia; Edite Pereira
Journal:  Cureus       Date:  2022-03-11

5.  Medication Safety: Experiential Learning for Pharmacy Students and Staff in a Hospital Setting.

Authors:  Linda V Graudins; Michael J Dooley
Journal:  Pharmacy (Basel)       Date:  2016-11-17

6.  Assessing Medical Prescription Forms as a Communication Tool in Trans-European Health Care.

Authors:  Afonso Miguel Cavaco; Miguel Mourato; Sofia Ferreira; Selen Yeğenoğlu
Journal:  J Res Pharm Pract       Date:  2018 Jan-Mar

7.  Medication Error- A Case Report of Misadventure with Methotrexate.

Authors:  Anup Singh; Aru Chhabra Handa
Journal:  JNMA J Nepal Med Assoc       Date:  2018 Mar-Apr       Impact factor: 0.406

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.